SE9901573D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9901573D0
SE9901573D0 SE9901573A SE9901573A SE9901573D0 SE 9901573 D0 SE9901573 D0 SE 9901573D0 SE 9901573 A SE9901573 A SE 9901573A SE 9901573 A SE9901573 A SE 9901573A SE 9901573 D0 SE9901573 D0 SE 9901573D0
Authority
SE
Sweden
Prior art keywords
compounds
solvates
pharmaceutically acceptable
new compounds
carboxypeptidase
Prior art date
Application number
SE9901573A
Other languages
English (en)
Swedish (sv)
Inventor
Marcel Linschoten
Magnus Polla
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9901573A priority Critical patent/SE9901573D0/xx
Publication of SE9901573D0 publication Critical patent/SE9901573D0/xx
Priority to ARP000102084A priority patent/AR023819A1/es
Priority to ARP000102083A priority patent/AR034241A1/es
Priority to MYPI20001883A priority patent/MY128014A/en
Priority to MYPI20001884A priority patent/MY126962A/en
Priority to TR2001/03151T priority patent/TR200103151T2/xx
Priority to CA002371213A priority patent/CA2371213C/en
Priority to TR2001/03153T priority patent/TR200103153T2/xx
Priority to KR1020017014011A priority patent/KR100755152B1/ko
Priority to US09/600,659 priority patent/US6974800B1/en
Priority to CA002371217A priority patent/CA2371217A1/en
Priority to CNB008094829A priority patent/CN1263739C/zh
Priority to US09/600,661 priority patent/US7071175B1/en
Priority to CNB008071284A priority patent/CN100518820C/zh
Priority to AU47902/00A priority patent/AU771760B2/en
Priority to TW089108401A priority patent/TWI232106B/zh
Priority to MXPA01011055A priority patent/MXPA01011055A/es
Priority to BR0010257-1A priority patent/BR0010257A/pt
Priority to NZ515063A priority patent/NZ515063A/en
Priority to DE60043297T priority patent/DE60043297D1/de
Priority to JP2000615388A priority patent/JP2002543184A/ja
Priority to ES00925845T priority patent/ES2335383T3/es
Priority to EP00930001A priority patent/EP1180098A1/en
Priority to IL14595400A priority patent/IL145954A0/xx
Priority to NZ515062A priority patent/NZ515062A/en
Priority to MXPA01011044A priority patent/MXPA01011044A/es
Priority to EEP200100574A priority patent/EE04490B1/et
Priority to KR1020017014009A priority patent/KR100725206B1/ko
Priority to PCT/SE2000/000834 priority patent/WO2000066557A1/en
Priority to SK1546-2001A priority patent/SK15462001A3/sk
Priority to CZ20013932A priority patent/CZ20013932A3/cs
Priority to BR0010255-5A priority patent/BR0010255A/pt
Priority to PL354360A priority patent/PL200932B1/pl
Priority to PCT/SE2000/000847 priority patent/WO2000066152A1/en
Priority to SK1565-2001A priority patent/SK15652001A3/sk
Priority to IL14595100A priority patent/IL145951A0/xx
Priority to AU44472/00A priority patent/AU763772B2/en
Priority to TW089108400A priority patent/TWI232105B/zh
Priority to CZ20013930A priority patent/CZ20013930A3/cs
Priority to RU2001128158/15A priority patent/RU2242992C2/ru
Priority to AT00925845T priority patent/ATE447964T1/de
Priority to JP2000615036A priority patent/JP2002543148A/ja
Priority to EEP200100578A priority patent/EE200100578A/et
Priority to EP00925845A priority patent/EP1181048B1/en
Priority to RU2001128159/04A priority patent/RU2244708C2/ru
Priority to HU0202876A priority patent/HUP0202876A3/hu
Priority to PL356119A priority patent/PL203505B1/pl
Priority to HU0201615A priority patent/HUP0201615A3/hu
Priority to NO20015308A priority patent/NO20015308L/no
Priority to ZA200108968A priority patent/ZA200108968B/xx
Priority to IS6139A priority patent/IS6139A/is
Priority to IS6140A priority patent/IS6140A/is
Priority to NO20015383A priority patent/NO321377B1/no
Priority to HK02104300.5A priority patent/HK1042303A1/zh
Priority to HK02104301.4A priority patent/HK1042442B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9901573A 1999-05-03 1999-05-03 New compounds SE9901573D0 (sv)

Priority Applications (55)

Application Number Priority Date Filing Date Title
SE9901573A SE9901573D0 (sv) 1999-05-03 1999-05-03 New compounds
ARP000102084A AR023819A1 (es) 1999-05-03 2000-04-28 FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
ARP000102083A AR034241A1 (es) 1999-05-03 2000-04-28 Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento
MYPI20001883A MY128014A (en) 1999-05-03 2000-05-02 Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
MYPI20001884A MY126962A (en) 1999-05-03 2000-05-02 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
TR2001/03151T TR200103151T2 (tr) 1999-05-03 2000-05-03 Karboksipeptidaz U inhibitörü ile trombin inhibitörünü içeren farmasötik bir formülasyon.
CA002371213A CA2371213C (en) 1999-05-03 2000-05-03 Inhibitors of carboxypeptidase u
TR2001/03153T TR200103153T2 (tr) 1999-05-03 2000-05-03 Yeni bileşimler
KR1020017014011A KR100755152B1 (ko) 1999-05-03 2000-05-03 신규 화합물
US09/600,659 US6974800B1 (en) 1999-05-03 2000-05-03 Formulations comprising an inhibitor of carboxypeptidase U and A thrombin inhibitor
CA002371217A CA2371217A1 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
CNB008094829A CN1263739C (zh) 1999-05-03 2000-05-03 羧肽酶u抑制化合物、其制备方法、含有该化合物的药物组合物及其用途
US09/600,661 US7071175B1 (en) 1999-05-03 2000-05-03 Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors
CNB008071284A CN100518820C (zh) 1999-05-03 2000-05-03 含有羧肽酶u抑制剂和凝血酶抑制剂的药物制剂
AU47902/00A AU771760B2 (en) 1999-05-03 2000-05-03 New compounds
TW089108401A TWI232106B (en) 1999-05-03 2000-05-03 Pharmaceutical compositions and kits of parts for the treatment of a patient suffering from or susceptible to a condition in which inhibition of thrombin and/or inhibition of carboxypeptidase U are required or desired
MXPA01011055A MXPA01011055A (es) 1999-05-03 2000-05-03 Nuevos compuestos que inhiben las carboxipeptidasas basicas..
BR0010257-1A BR0010257A (pt) 1999-05-03 2000-05-03 Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados
NZ515063A NZ515063A (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase U and a thrombin inhibitor
DE60043297T DE60043297D1 (de) 1999-05-03 2000-05-03 Eine pharmazeutische formulierung, enthaltend einen inhibitor der carboxypeptidase a und einen thrombin-inhibitor
JP2000615388A JP2002543184A (ja) 1999-05-03 2000-05-03 新規化合物
ES00925845T ES2335383T3 (es) 1999-05-03 2000-05-03 Una formulacion farmaceutica que contiene un inhibidor de carboxipeptidasa y un inhibidor de trombina.
EP00930001A EP1180098A1 (en) 1999-05-03 2000-05-03 New compounds
IL14595400A IL145954A0 (en) 1999-05-03 2000-05-03 A new inhibitor of carboxypeptidase u
NZ515062A NZ515062A (en) 1999-05-03 2000-05-03 New compounds, and pharmaceutically acceptable salts thereof, which inhibit basic carboxypeptidases
MXPA01011044A MXPA01011044A (es) 1999-05-03 2000-05-03 Formulacion farmaceutica que contiene un inhibidor de carboxipeptidasa u y un inhibidor de trombina..
EEP200100574A EE04490B1 (et) 1999-05-03 2000-05-03 Ühend, selle valmistamise meetod ning kasutamine meditsiinis
KR1020017014009A KR100725206B1 (ko) 1999-05-03 2000-05-03 카르복시펩티다제 ｕ 억제제 및 트롬빈 억제제를 함유하는제약 제제
PCT/SE2000/000834 WO2000066557A1 (en) 1999-05-03 2000-05-03 New compounds
SK1546-2001A SK15462001A3 (sk) 1999-05-03 2000-05-03 Deriváty etántiolu, spôsoby ich prípravy, farmaceutické prípravky s ich obsahom a ich použitie na liečenie
CZ20013932A CZ20013932A3 (cs) 1999-05-03 2000-05-03 Farmaceutický prostředek obsahující inhibitor karboxyperoxidasy U a inhibitor thrombinu
BR0010255-5A BR0010255A (pt) 1999-05-03 2000-05-03 Formulação farmacêutica, kit de partes, método para tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da trombina e/ou inibição da carboxipeptidase u são requeridas ou desejadas, e, uso de uma formulação
PL354360A PL200932B1 (pl) 1999-05-03 2000-05-03 Nowe związki, środek farmaceutyczny i zastosowanie nowych związków
PCT/SE2000/000847 WO2000066152A1 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
SK1565-2001A SK15652001A3 (sk) 1999-05-03 2000-05-03 Farmaceutický prípravok obsahujúci inhibítor karboxypeptidázy U a inhibítor trombínu
IL14595100A IL145951A0 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
AU44472/00A AU763772B2 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase U and a thrombin inhibitor
TW089108400A TWI232105B (en) 1999-05-03 2000-05-03 Novel compounds and their preparation process and pharmaceutical formulation containing the same
CZ20013930A CZ20013930A3 (cs) 1999-05-03 2000-05-03 Nové sloučeniny
RU2001128158/15A RU2242992C2 (ru) 1999-05-03 2000-05-03 Фармацевтический препарат, содержащий ингибитор карбоксипептидазы u и ингибитор тромбина
AT00925845T ATE447964T1 (de) 1999-05-03 2000-05-03 Eine pharmazeutische formulierung, enthaltend einen inhibitor der carboxypeptidase a und einen thrombin-inhibitor
JP2000615036A JP2002543148A (ja) 1999-05-03 2000-05-03 カルボキシペプチダーゼｕ阻害剤とトロンビン阻害剤とを含有する医薬製剤
EEP200100578A EE200100578A (et) 1999-05-03 2000-05-03 Karboksüpeptidaasi U inhibiitorit ja trombiini inhibiitorit sisaldav ravimpreparaat
EP00925845A EP1181048B1 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
RU2001128159/04A RU2244708C2 (ru) 1999-05-03 2000-05-03 Серусодержащие соединения, способы их получения и фармацевтические препараты на их основе
HU0202876A HUP0202876A3 (en) 1999-05-03 2000-05-03 Carboxypeptidase u inhibiting new compounds, process for their preparation and pharmaceutical compositions containing them and their use
PL356119A PL203505B1 (pl) 1999-05-03 2000-05-03 Preparat farmaceutyczny zawieraj acy inhibitor karboksypeptydazy U i inhibitor trombiny, zestaw sk ladników i zastosowanie preparatu farmaceutycznego
HU0201615A HUP0201615A3 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
NO20015308A NO20015308L (no) 1999-05-03 2001-10-30 En farmasoytisk formulering som inneholder en inhibitor av karboksypeptidase U og A trombininhibitor
ZA200108968A ZA200108968B (en) 1999-05-03 2001-10-30 New compounds.
IS6139A IS6139A (is) 1999-05-03 2001-11-01 Ný efnasambönd
IS6140A IS6140A (is) 1999-05-03 2001-11-01 Lyfjablanda sem inniheldur hemil karboxýpeptíðasaU og þrombínhemil
NO20015383A NO321377B1 (no) 1999-05-03 2001-11-02 Nye forbindelser
HK02104300.5A HK1042303A1 (zh) 1999-05-03 2002-06-06 新的化合物
HK02104301.4A HK1042442B (zh) 1999-05-03 2002-06-06 含有羧肽酶u抑制劑和凝血酶抑制劑的藥物製劑

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901573A SE9901573D0 (sv) 1999-05-03 1999-05-03 New compounds

Publications (1)

Publication Number Publication Date
SE9901573D0 true SE9901573D0 (sv) 1999-05-03

Family

ID=20415426

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901573A SE9901573D0 (sv) 1999-05-03 1999-05-03 New compounds

Country Status (27)

Country Link
US (1) US7071175B1 (et)
EP (1) EP1180098A1 (et)
JP (1) JP2002543184A (et)
KR (1) KR100755152B1 (et)
CN (1) CN1263739C (et)
AR (1) AR034241A1 (et)
AU (1) AU771760B2 (et)
BR (1) BR0010257A (et)
CA (1) CA2371213C (et)
CZ (1) CZ20013930A3 (et)
EE (1) EE04490B1 (et)
HK (1) HK1042303A1 (et)
HU (1) HUP0202876A3 (et)
IL (1) IL145954A0 (et)
IS (1) IS6139A (et)
MX (1) MXPA01011055A (et)
MY (1) MY128014A (et)
NO (1) NO321377B1 (et)
NZ (1) NZ515062A (et)
PL (1) PL200932B1 (et)
RU (1) RU2244708C2 (et)
SE (1) SE9901573D0 (et)
SK (1) SK15462001A3 (et)
TR (1) TR200103153T2 (et)
TW (1) TWI232105B (et)
WO (1) WO2000066557A1 (et)
ZA (1) ZA200108968B (et)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828566B2 (en) * 1997-07-22 2004-12-07 Hitachi Ltd Method and apparatus for specimen fabrication
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
MXPA02002671A (es) 1999-09-14 2002-07-30 Meiji Seika Kaisha Derivado de acido fosfonico que tiene actividad inhibidora contra la carboxipeptidasa b.
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
BR0307033A (pt) 2002-01-22 2004-12-07 Pfizer ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
EP1497300A2 (en) * 2002-03-21 2005-01-19 Schering Aktiengesellschaft Plasma carboxypeptidase b inhibitors
CA2486402C (en) 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
SE0201837D0 (sv) * 2002-06-14 2002-06-14 Astrazeneca Ab Chemical compounds
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2009290474A1 (en) 2008-09-11 2010-03-18 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
CA2748587A1 (en) 2009-01-20 2010-07-29 Pfizer Inc. Substituted pyrazinone amides
CN102388038B (zh) 2009-03-11 2014-04-23 辉瑞大药厂 用作葡糖激酶活化剂的苯并呋喃基衍生物
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102249992A (zh) * 2011-07-05 2011-11-23 广东工业大学 一种制备2-氨基异烟酸的方法
US9919939B2 (en) 2011-12-06 2018-03-20 Delta Faucet Company Ozone distribution in a faucet
WO2014198620A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
AR099134A1 (es) * 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
CN115093008B (zh) 2015-12-21 2024-05-14 德尔塔阀门公司 包括消毒装置的流体输送系统
USD879309S1 (en) 2018-08-09 2020-03-24 Scott Specialties, Inc. Maternity support

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
FR1393338A (fr) 1964-01-08 1965-03-26 Rech S Pharma Et Scient Nouveau dérivé de la cystéine et sa préparation
US3766206A (en) 1971-11-03 1973-10-16 Pfizer 18beta-glycyrrheting acid amides useful as antiulcer agents
FR2266502A1 (en) 1974-04-08 1975-10-31 Synpharm Sa N-(2-thenoyl)-cysteine and esters - with mucolytic activity, prepd. from cysteine (esters) and thenoyl chloride
US4113715A (en) 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
US4177277A (en) 1977-01-17 1979-12-04 E. R. Squibb & Sons, Inc. Method for alleviating hypertension
JPS545949A (en) 1977-06-16 1979-01-17 Hisamitsu Pharmaceut Co Inc Novel cyclohexanecarboxylic acid and its derivatives
FR2430945A2 (fr) 1978-07-12 1980-02-08 Chauvin Blache Lab Nouveaux derives de la cysteine, leur procede de fabrication et leur application en therapeutique
US4537727A (en) 1982-11-12 1985-08-27 Eli Lilly And Company Process for recovering 2-acetylthiomethyl-5-aminopentanoic acid
EP0136883B1 (en) * 1983-10-03 1987-11-25 E.R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4708965A (en) 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
JPS62270555A (ja) * 1986-05-19 1987-11-24 Dainippon Pharmaceut Co Ltd スルホン酸誘導体およびその塩
EP0318859A3 (en) 1987-12-03 1990-08-16 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
JPH01254654A (ja) * 1988-04-01 1989-10-11 Dainippon Pharmaceut Co Ltd スルホン酸の誘導体及びその塩
EP0361365A1 (en) * 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
DE3838467C2 (de) 1988-11-12 1998-12-10 Agfa Gevaert Ag Fotografisches Aufzeichnungsmaterial
ZA911813B (en) 1990-08-09 1991-12-24 Sankyo Co (benzhydryloxyethylpiperidyl)aliphatic acid derivatives and their use in the treatment of allergies and asthma
IT1249650B (it) 1991-05-29 1995-03-09 Poli Ind Chimica Spa N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
GB9122016D0 (en) 1991-10-16 1991-11-27 Glaxo Group Ltd Chemical compounds
IT1266571B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
US5470834A (en) * 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
DE4441873A1 (de) * 1994-11-24 1996-05-30 Wella Ag Mittel zur dauerhaften Haarverformung
JP3874455B2 (ja) 1996-06-27 2007-01-31 新日本製鐵株式会社 フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤

Also Published As

Publication number Publication date
SK15462001A3 (sk) 2002-11-06
KR100755152B1 (ko) 2007-09-04
CZ20013930A3 (cs) 2002-10-16
CN1263739C (zh) 2006-07-12
TR200103153T2 (tr) 2002-04-22
AU771760B2 (en) 2004-04-01
PL354360A1 (en) 2004-01-12
HUP0202876A3 (en) 2005-07-28
NO321377B1 (no) 2006-05-02
BR0010257A (pt) 2002-02-13
HUP0202876A2 (hu) 2003-01-28
PL200932B1 (pl) 2009-02-27
RU2244708C2 (ru) 2005-01-20
EE200100574A (et) 2003-02-17
MY128014A (en) 2007-01-31
HK1042303A1 (zh) 2002-08-09
IL145954A0 (en) 2002-11-10
AR034241A1 (es) 2004-02-18
NZ515062A (en) 2004-04-30
JP2002543184A (ja) 2002-12-17
NO20015383L (no) 2001-12-21
IS6139A (is) 2001-11-01
EP1180098A1 (en) 2002-02-20
US7071175B1 (en) 2006-07-04
ZA200108968B (en) 2003-09-05
CA2371213C (en) 2009-11-10
MXPA01011055A (es) 2002-06-04
CN1358174A (zh) 2002-07-10
EE04490B1 (et) 2005-06-15
TWI232105B (en) 2005-05-11
KR20020010630A (ko) 2002-02-04
NO20015383D0 (no) 2001-11-02
WO2000066557A1 (en) 2000-11-09
AU4790200A (en) 2000-11-17
CA2371213A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
SE9901573D0 (sv) New compounds
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
SE0202462D0 (sv) Novel use
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
CY1107753T1 (el) 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
SE0002476D0 (sv) New compounds
SE0102440D0 (sv) New compound
HK1045464A1 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
SE9901572D0 (sv) New compounds
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
HU9802897D0 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
SE9900190D0 (sv) New compounds
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
ATE301997T1 (de) Antivirale therapie
SE0301904D0 (sv) Novel imidazopyridine compound II with therapeutic effect
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
TW200500330A (en) Pharmaceutical composition
UY27855A1 (es) Compuestos quimicos